Revolution Medicines, Inc. Other Current Liabilities
Revolution Medicines, Inc. (RVMD) had Other Current Liabilities of $5.14 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Other Liabilities, Current $5.14M.
- 2026-03-31: Other Liabilities, Current $3.26M.
- 2025-12-31: Other Liabilities, Current $7.86M.
- 2025-09-30: Other Liabilities, Current $8.24M.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $5.14M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $3.26M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $7.86M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $8.24M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $462.00K 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $651.00K 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $583.00K 10-K · filed 2026-02-25 | |
| 2024-09-30 | $1.28M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $657.00K 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $744.00K 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $3.90M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $480.00K 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $350.00K 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $397.00K 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $505.00K 10-K · filed 2024-02-26 | |
| 2022-09-30 | $488.00K 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $647.00K 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $280.00K 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $311.00K 10-K · filed 2023-02-27 | |
| 2021-09-30 | $125.00K 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $99.00K 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $104.00K 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $97.00K 10-K · filed 2022-02-28 | |
| 2020-09-30 | $91.00K 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $78.00K 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $724.00K 10-Q · filed 2020-05-14 | |
| 2019-12-31 | $1.05M 10-K · filed 2021-03-02 | $876.00K 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |